CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III
CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III
CellProthera和biocardia在ProtheraCytes用于急性心肌梗死的合作II期临床试验中取得成功，并计划继续关系至III期。
CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in combination with the standard of care, suggested an effective solution for preventing heart failure progression in the patients at high risk following a heart attack.
CellProthera的I/IIb EXCELLENt试验的临床结果表明，在与标准板治疗联合给药的情况下，ProtheraCytes的经内心膜注射对急性心肌梗塞有很好的可行性，该方案对于高风险患者防止心脏衰竭进展具有有效的解决方案。